Get the Daily Brief
Latest Biotech News
Parse Biosciences scores patent win — single‑cell IP battle shifts
Parse Biosciences secured a court ruling that invalidated a Scale Biosciences patent now owned by 10x Genomics, removing one asserted claim in ongoing patent litigation. A U.S. District Court...
Consortium publishes pan‑disease blood atlas — 59 conditions profiled in Science
An international consortium released a pan‑disease plasma proteome atlas profiling blood proteins across 59 diseases and multiple cohorts; the work appeared in Science. The project measured...
Mammoth plans first trial: monkey data show durable triglyceride edits
Mammoth Biosciences disclosed nonhuman primate data for its lead in vivo gene‑editing program aimed at lowering triglycerides, and announced plans for a first human trial. The company reported...
Nature maps somatic selection across populations — deep sequencing reveals drivers
A Nature study released population‑scale analyses of somatic mutations and selection across human tissues using ultra‑deep duplex sequencing. The authors combined very high‑coverage sequencing...
Novo buys Akero for $4.7B — adds FGF21 fibrosis candidate
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash to secure efruxifermin, an FGF21 analogue that showed fibrosis reversal signals in a Phase IIb study. The deal transfers...
Pan-disease proteome: SciLifeLab maps blood proteins across 59 diseases
An international consortium led by SciLifeLab and KTH published a large-scale proteomic atlas in Science profiling more than 9,000 blood samples across 59 diseases using Olink’s Explore/Explore HT...
Updated NanoSeq finds pre‑oncogenic somatic variants — cheaper targeted sequencing
Wellcome Sanger researchers released an updated NanoSeq method that adapts duplex sequencing for targeted panels, offering a lower‑cost approach to profile rare somatic variants across hundreds of...
Intellia clinical update: in vivo LNP programs show durable biology
Intellia provided a clinical update on its in‑vivo LNP gene‑editing programs at ESGCT, with CSO Birgit Schultes reporting multi‑year biomarker suppression in some cohorts and sustained...
Tempus wins $60.5M ARPA‑H contract — supplies testing for ADAPT cancer program
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to support the ADAPT precision cancer therapy program. Under the award, Tempus will supply genomic and transcriptomic testing (xR...
Court invalidates single‑cell patent — Parse Bio defeats Scale/10x claim
A U.S. district court memorandum held claims in US Patent No. 11,634,752 (owned by Scale Biosciences/10x Genomics) invalid for lack of written description and enablement after Parse Biosciences...
Programmable proteins: Boolean logic gates steer precision drug delivery
Researchers at the University of Washington published a Nature Chemical Biology proof‑of‑principle for 'logic‑programmed' proteins that autonomously present therapeutic cargo only when defined...
ARPA‑H backs in‑vivo cell therapies — Tessera lands $41.3M award
ARPA‑H awarded multiple teams funding to advance in‑vivo cell and gene therapy platforms; Tessera Therapeutics received up to $41.3 million for its EMBODY program to engineer immune cells inside...
Mammoth moves to clinic: first trial planned for triglyceride‑lowering edit
Mammoth Biosciences disclosed preclinical nonhuman primate data and announced plans for a first clinical trial of its lead gene‑editing program aimed at permanently lowering triglycerides....
FDA updates Xeloda label — DPYD genetic testing now recommended
The FDA revised Genentech’s Xeloda (capecitabine) label to explicitly recommend pre‑treatment DPYD genetic testing to identify patients at risk for severe fluoropyrimidine toxicities and to avoid...
Novo buys Akero for $4.7B – stakes claim in MASH
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash to add efruxifermin, an FGF21 analogue in late‑stage development for metabolic dysfunction‑associated steatohepatitis...
Pan‑disease proteome atlas maps signatures across 59 diseases
An international consortium published a pan‑disease proteomic atlas profiling thousands of blood samples to map protein changes across 59 diseases, providing an open resource for biomarker...
Proteins that decide: Boolean logic programs drug delivery
Researchers at the University of Washington reported engineering proteins that perform Boolean logic in biological environments to control therapeutic localization and release. Published in Nature...
Nanoparticle 'super adjuvant' prevents tumors in mice – multi‑cancer effect
University of Massachusetts Amherst researchers reported a nanoparticle vaccine platform that, when paired with cancer‑specific antigens, prevented tumor formation and metastasis in multiple mouse...
Tempus wins $60.5M ARPA‑H contract to support precision cancer program
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to provide testing and CRO services for the ADAPT precision cancer therapy program. Under the award, Tempus will supply RNA‑seq,...
Federal court tosses single‑cell patent — 10x/Scale IP shaken
A U.S. District Court judge invalidated a Scale Biosciences (now part of 10x Genomics) patent asserted against Parse Biosciences, ruling the claims failed written description and enablement...